Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Breast 4Head & Neck 2Gynecologic 1CNS 1

Conditions

Neurofibromatosis 1 1Neurofibroma, Plexiform 1

Interventions

Radiotherapy 64Temozolomide 59Vincristine 33Cyclophosphamide 32Carboplatin 30Radiosurgery 26Etoposide 25Cisplatin 25Lomustine 24Magnetic Resonance Spectroscopy 19Filgrastim 17Doxorubicin 15Bevacizumab 15Radiation 13Specimen Handling 12Granulocyte Colony-Stimulating Factor 12Surgical Procedures, Operative 11Isotretinoin 11Melphalan 10Carmustine 10Procarbazine 9Platinum 9Peripheral Blood Stem Cell Transplantation 9Chemotherapy, Adjuvant 9etoposide phosphate 7Topotecan 71,2-diaminocyclohexaneplatinum II citrate 7sargramostim 6Thiotepa 6Radiotherapy, Intensity-Modulated 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Control Groups × CNS × Clear all
NCT05913037 2025-03-06

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 3 Active not recruiting
167 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡